Submitted:
24 December 2025
Posted:
24 December 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study Setting
2.2. Study Design and Population
2.3. Sample Collection and Laboratory Procedures
2.4. Malaria Diagnosis
2.5. PCR-Based Malaria Detection
2.6. Immunological Biomarker Quantification
2.6.1. Cytokine Quantification
2.6.2. Antibody Quantification
2.7. Histological Assessment of Placental Malaria
2.8. Data Analysis
2.8.1. Statistical Analyses
2.8.2. Principal Component Analysis (PCA)
2.8.3. Cluster Stability via Bootstrapping
- The Approximately Unbiased (AU) p-value, based on multiscale bootstrap resampling
- The Bootstrap Probability (BP), based on standard resampling
3. Results
3.1. Demographic Characteristics
3.2. Descriptive Statistics of Immunological Biomarkers Immediately After Delivery
3.3. Immunological Profiles of the Study Population Independently to Their Malaria Status
- Cluster 1: Low-inflammatory profile: characterized by reduced IL-6 and TNF-α.
- Cluster 2: TNF-α–dominant profile: elevated TNF-α with moderate IL-6.
- Cluster 3: Highly pro-inflammatory profile: marked by simultaneous elevation of IL-6 and TNF-α.
3.4. Cluster Stability via Bootstrapping
3.5. Cluster Analysis According to the Malaria Status of Primigravid Women
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
| IL | Interleukin |
| TNF-α | Tumor Necrosis Factor-alpha |
| IFN-γ | Interferon-gamma |
| IPTp-SP | Intermittent Preventive Treatment in Pregnancy with Sulfadoxine–Pyrimethamine |
| PfCSP | Plasmodium falciparum Circumsporozoite Protein |
| PfAMA-1 | Plasmodium falciparum Apical Membrane Antigen 1 |
| EBA-175 | Erythrocyte Binding Antigen-175 |
| DBS | Dried Blood Spot |
| ELISA | Enzyme-Linked Immunosorbent Assay |
| PCA | Principal Component Analysis |
| HDSS | Health and Demographic Surveillance System |
| ANC | Antenatal Care |
| RDT | Rapid Diagnostic Test |
| OD | Optical Density |
| CRUN | Clinical Research Unit of Nanoro |
References
- WHO (2023) World malaria report 2023. https://www.who.int/publications/i/item/9789240086173. Accessed 28 Oct 2024.
- Desai M, Kuile FO ter, Nosten F, et al. (2007) Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 7:93–104. [CrossRef]
- Rogerson SJ, Hviid L, Duffy PE, et al. (2007) Malaria in pregnancy: pathogenesis and immunity. Lancet Infect Dis 7:105–117. [CrossRef]
- RW S, BL N, ME P, C M (2001) The burden of malaria in pregnancy in malaria-endemic areas. Am J Tropical Medicine Hyg 64:28–35. [CrossRef]
- Tomlinson A, Semblat J-P, Gamain B, Chêne A (2021) VAR2CSA-Mediated Host Defense Evasion of Plasmodium falciparum Infected Erythrocytes in Placental Malaria. Front Immunol 11:624126. [CrossRef]
- Doritchamou JY, Renn JP, Jenkins B, et al. (2022) A single full-length VAR2CSA ectodomain variant purifies broadly neutralizing antibodies against placental malaria isolates. eLife 11:e76264. [CrossRef]
- Ataíde R, Mayor A, Rogerson SJ (2014) Malaria, primigravidae, and antibodies: knowledge gained and future perspectives. Trends Parasitol 30:85–94. [CrossRef]
- Fried M, Nosten F, Brockman A, et al. (1998) Maternal antibodies block malaria. Nature 395:851–852. [CrossRef]
- Fried M, Kurtis JD, Swihart B, et al. (2018) Antibody levels to recombinant VAR2CSA domains vary with Plasmodium falciparum parasitaemia, gestational age, and gravidity, but do not predict pregnancy outcomes. Malar J 17:106. [CrossRef]
- Ruizendaal E, Schallig HDFH, Bradley J, et al. (2017) Interleukin-10 and soluble tumor necrosis factor receptor II are potential biomarkers of Plasmodium falciparum infections in pregnant women: a case-control study from Nanoro, Burkina Faso. Biomark Res 5:34. [CrossRef]
- Diallo S, Roberts SA, Gies S, et al. (2020) Malaria early in the first pregnancy: Potential impact of iron status. Clin Nutr 39:204–214. [CrossRef]
- Rénia L, Goh YS (2016) Malaria Parasites: The Great Escape. Front Immunol 7:463. [CrossRef]
- Jäschke A, Coulibaly B, Remarque EJ, et al. (2017) Merozoite Surface Protein 1 from Plasmodium falciparum Is a Major Target of Opsonizing Antibodies in Individuals with Acquired Immunity against Malaria. Clin Vaccine Immunol 24:. [CrossRef]
- Li S, Rouphael N, Duraisingham S, et al. (2014) Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol 15:195–204. [CrossRef]
- Jolliffe IT, Cadima J (2016) Principal component analysis: a review and recent developments. Philos Trans R Soc A: Math, Phys Eng Sci 374:20150202. [CrossRef]
- Xu R, II DW (2005) Survey of Clustering Algorithms. IEEE Trans Neural Netw 16:645–678. [CrossRef]
- Derra K, Rouamba E, Kazienga A, et al. (2012) Profile: Nanoro Health and Demographic Surveillance System. Int J Epidemiology 41:1293–1301. [CrossRef]
- Zango SH, Lingani M, Valea I, et al. (2020) Malaria and curable sexually transmitted infections in pregnant women: A two-years observational study in rural Burkina Faso. PLoS ONE 15:e0242368. [CrossRef]
- Kattenberg JH, Tahita CM, Versteeg IAJ, et al. (2012) Evaluation of Antigen Detection Tests, Microscopy, and Polymerase Chain Reaction for Diagnosis of Malaria in Peripheral Blood in Asymptomatic Pregnant Women in Nanoro, Burkina Faso. Am Soc Trop Med Hyg 87:251–256. [CrossRef]
- Fuente IM– de la, Tahita MC, Bérenger K, et al. (2024) Malaria diagnosis challenges and pfhrp2 and pfhrp3 gene deletions using pregnant women as sentinel population in Nanoro region, Burkina Faso. Pathog Glob Heal 118:481–491. [CrossRef]
- Zango SH, Lingani M, Valea I, et al. (2021) Association of malaria and curable sexually transmitted infections with pregnancy outcomes in rural Burkina Faso. BMC Pregnancy Childbirth 21:722. [CrossRef]
- Tahita MC, Tinto H, Menten J, et al. (2013) Clinical signs and symptoms cannot reliably predict Plasmodium falciparum malaria infection in pregnant women living in an area of high seasonal transmission. Malaria J 12:464–464. [CrossRef]
- MoH (2024) Ministry of Health’s 2023 Health Indicators Dashboard.
- Consortium C, Scott S, D’Alessandro U, et al. (2019) Community-based Malaria Screening and Treatment for Pregnant Women Receiving Standard Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: A Multicenter (The Gambia, Burkina Faso, and Benin) Cluster-randomized Controlled Trial. Clin Infect Dis Official Publ Infect Dis Soc Am 68:586–596. [CrossRef]
- Ousmane T, Hermann S, Isidore Y W, et al. (2018) Naturally acquired antibody to DBL5 and ID1-ID2a dynamics in primigravid women during postpartum in a rural setting of Burkina Faso. African Journal of Immunology Research 5:453–462.
- Wooden J, Kyes S, Sibley CH (1993) PCR and strain identification in Plasmodium falciparum. Parasitol Today 9:303–305. [CrossRef]
- Singh RP, Nie X, Singh M, et al. (2002) Sodium sulphite inhibition of potato and cherry polyphenolics in nucleic acid extraction for virus detection by RT-PCR. J Virol Methods 99:123–131. [CrossRef]
- Perez-Mazliah D, Langhorne J (2015) CD4 T-Cell Subsets in Malaria: TH1/TH2 Revisited. Front Immunol 5:671. [CrossRef]
- BULMER JN, RASHEED FN, FRANCIS N, et al. (1993) Placental malaria. I. Pathological classification. Histopathology 22:211–218. [CrossRef]
- Moormann AM, Sullivan AD, Rochford RA, et al. (1999) Malaria and Pregnancy: Placental Cytokine Expression and Its Relationship to Intrauterine Growth Retardation. J Infect Dis 180:1987–1993. [CrossRef]
- Othoro C, Lal AA, Nahlen B, et al. (1999) A Low Interleukin-10 Tumor Necrosis Factor-α Ratio Is Associated with Malaria Anemia in Children Residing in a Holoendemic Malaria Region in Western Kenya. J Infect Dis 179:279–282. [CrossRef]


| Characteristic | Value |
| Age (years), Mean ± SD | 19 ± 1.6 |
| Anaemia at delivery (Hb≤ 11g/dl), n (%) | 20 (60.6) |
| IPTp-SP doses, n (%) | |
| ≤ 2 doses | 17 (51.5) |
| > 2 doses | 16 (48.5) |
| Peripheral parasite density at delivery, Mean (min-max) | 540.9 parasites/µL (0–5584) |
| Malaria infection at delivery, n (%) | 16 (48.5) |
| Placental malaria status (N = 21), n (%) | |
| – Active | 1 (4.8) |
| – Past only | 4 (19.1) |
| – No infection | 16 (76.2) |
| Delivery conditions, n (%) | |
| Dystocia | 6 (18.2) |
| Period of delivery, n (%) | |
| High transmission season | 20 (60.6) |
| Low transmission season | 13 (39.4) |
| Biomarker | Mean | Std. Dev | Q1 | Median | Q3 |
| IgGT_PfAMA1 | 0.625 | 0.380 | 0.381 | 0.477 | 0.845 |
| IgGT_EBA175 | 2.160 | 1.164 | 1.043 | 2.567 | 3.292 |
| IgGT_PfCSP | 1.328 | 0.997 | 0.540 | 0.960 | 1.864 |
| IL-10 | 15.530 | 22.507 | 7.014 | 9.031 | 13.128 |
| IL-4 | 30.999 | 17.496 | 21.827 | 26.277 | 31.600 |
| IL-6 | 186.873 | 328.056 | 31.919 | 57.103 | 153.484 |
| IFN-γ | 0.035 | 0.029 | 0.009 | 0.023 | 0.063 |
| TNF-α | 189.689 | 270.024 | 10.438 | 21.656 | 364.931 |
| Mean | Std.Dev | Q1 | Median | Q3 | |
| IgGT_AMA1 | 0.665 | 0.399 | 0.372 | 0.595 | 0.954 |
| IgGT_EBA175 | 1.967 | 1.133 | 0.996 | 1.775 | 3.073 |
| IgGT_PfCSP | 1.411 | 1.114 | 0.473 | 1.174 | 2.318 |
| IL-10 | 17.463 | 26.550 | 6.812 | 9.155 | 13.966 |
| IL-4 | 28.171 | 14.549 | 20.440 | 23.454 | 31.600 |
| IL-6* | 75.910 | 85.140 | 27.608 | 47.585 | 95.485 |
| IFN-γ | 0.032 | 0.026 | 0.011 | 0.022 | 0.062 |
| TNF-α* | 25.439 | 30.029 | 7.838 | 15.044 | 28.751 |
| Mean | Std.Dev | Q1 | Median | Q3 | |
| IgGT_AMA1 | 0.472 | 0.194 | 0.382 | 0.434 | 0.550 |
| IgGT_EBA175 | 2.712 | 1.130 | 1.458 | 3.399 | 3.415 |
| IgGT_PfCSP | 0.935 | 0.530 | 0.673 | 0.952 | 1.371 |
| IL-10 | 7.674 | 1.812 | 6.998 | 8.410 | 8.674 |
| IL-4 | 33.127 | 15.944 | 22.497 | 29.439 | 37.097 |
| IL-6 | 152.564 | 129.522 | 31.178 | 95.791 | 263.601 |
| IFN-γ | 0.045 | 0.038 | 0.007 | 0.058 | 0.087 |
| TNF-α* | 551.411 | 177.349 | 364.931 | 605.935 | 698.965 |
| Mean | Std.Dev | Q1 | Median | Q3 | |
| IgGT_AMA1 | 0.669 | 0.582 | 0.289 | 0.380 | 1.339 |
| IgGT_EBA175 | 2.348 | 1.479 | 0.741 | 2.646 | 3.656 |
| IgGT_PfCSP | 1.606 | 0.833 | 0.960 | 1.312 | 2.546 |
| IL-10 | 19.039 | 7.862 | 13.128 | 16.029 | 27.962 |
| IL-4 | 47.721 | 35.773 | 24.123 | 30.159 | 88.881 |
| IL-6* | 1117.641 | 382.957 | 736.716 | 1113.609 | 1502.598 |
| IFN-γ | 0.035 | 0.031 | 0.005 | 0.031 | 0.068 |
| TNF-α* | 604.922 | 188.436 | 421.158 | 595.901 | 797.706 |
| Cluster | Malaria status | Total | ||||
| Infected | Non-Infected | |||||
| Profile 1 - (n, %) | 11 (47.83) | 12 (52.17) | 23 (69.70) | |||
| Profile 2 - (n, %) | 2 (28.57) | 5 (71.43) | 7 (21.21) | |||
| Profile 3 - (n, %) | 3 (100.00) | 0 (0.00) | 3 (9.09) | |||
| Total - (n, %) | 16 (48.48) | 17 (51.52) | 33 (100) | |||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).